Home > Quotes > PBE

PowerShares Dynamic Biotechnology & Genome Portfolio Stock Quote & Summary Data

Get PBE Alerts
*Delayed - data as of Jan. 29, 2015  -  Find a broker to begin trading PBE now

Community Rating:
Symbol List Views
FlashQuotes InfoQuotes
ETF Details
Summary Quote ETF Detail Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
ETF Headlines Market Stream
Short Interest Dividend History
 Save Stocks
1 Year Target
Today's High /Low  / 
Share Volume
90 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today's trading to the average daily volume. 141,680
Previous Close $ 52.85
52 Week High/Low $ 54.46 / $ 36.88
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. $ 535,900,000
Annualized dividend N/A
Ex Dividend Date N/A
Dividend Payment Date Dec. 31, 2014
Current Yield 0 %
Beta 0

Intraday Chart


The PowerShares Dynamic Biotechnology & Genome Portfolio seeks investment results that correspond generally to the price and yield (before the Fund's fees and expenses) of an equity index called the Dynamic Biotechnology & Genome Intellidex Index (the "Underlying Intellidex"). The Underlying Intellidex is comprised of stocks of 30 U.S. biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. These companies may include, for example, companies involved in the research, development or production of pharmaceuticals, including veterinary drugs. Stocks are selected principally on the basis of their capital appreciation potential as identified by NYSE Arca pursuant to a proprietary Intellidex methodology. The Fund will normally invest at least 80% of its total assets in common stocks of biotechnology companies and genome companies.

Underlying Index Dynamic Biotechnology & Genome Intellidex Index
Management Fee 0.63
Asset Class Equity
Leverage 1

News for PBE

Top Holdings
IDIX Idenix Pharmaceuticals 9.33%
ILMN Illumina Inc 4.76%
WAT Waters Corp 4.68%
AMGN Amgen Inc 4.57%
GILD Gilead Sciences 4.44%
BIIB Biogen Idec Inc 4.39%
ALXN Alexion Pharmaceuticals 4.26%
REGN Regeneron Pharmaceuticals 4.04%
ISIS Isis Pharmaceuticals 3.02%
SGEN Seattle Genetics 2.9%

Research Brokers before you trade

Want to trade FX?